Skip to content
ClinCalc Pro
Menu
Antifibrinolytic

Tranexamic Acid (Obstetric — PPH)

Brand names: Cyklokapron, Exacyl

In the obstetric setting tranexamic acid is an antifibrinolytic given intravenously as part of the management of postpartum haemorrhage to reduce bleeding and death from bleeding.

Dosing — not shown for this use

The product information we hold does not support a dose for this page's specific use, route or population, so none is shown. Follow your local or national guideline, and confirm against the product SmPC.

The licensed dosing — for the medicine's licensed uses, which may differ from this page's — is on Tranexamic Acid.

Clinical monograph

How it works

It inhibits plasminogen activation to plasmin, stabilising fibrin clot and limiting fibrinolysis at the placental bed and other bleeding sites.

Prescribing in practice

  • Early administration is critical, as benefit in postpartum haemorrhage falls markedly with delay, so it should be given as soon as possible after the onset of bleeding.
  • It is an adjunct to, not a replacement for, mechanical, uterotonic and resuscitative measures in major obstetric haemorrhage.
  • Caution applies with known thromboembolic disease, and rapid intravenous injection can cause hypotension.

Monitoring

Monitor ongoing blood loss, haemodynamic status and the response to the wider haemorrhage protocol rather than relying on the drug alone.

Counselling the patient

  • This medicine is given by a vein during heavy bleeding after birth to help control it.
  • It works alongside other treatments to stop the bleeding.
  • The team will watch your blood pressure and bleeding closely after it is given.

Evidence & guidelines

The WOMAN trial showed tranexamic acid reduces death due to bleeding in postpartum haemorrhage when given early, and it is recommended in UK obstetric haemorrhage guidance.

Reference: WOMAN Trial (Shakur et al, Lancet 2017); WHO PPH Management Guidelines 2022; RCOG Green-top 52; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.